Brookstone Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Brookstone Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,185	Closed	-$141K	–	923
2023 Q4	$141K	Hold	15,185	–	–	﹤0.01%	842
2023 Q3	$84.9K	Buy	15,185 +340	+2%	+$2.71K	﹤0.01%	809
2023 Q2	$121K	Hold	14,845	–	–	﹤0.01%	801
2023 Q1	$121K	Hold	14,845	–	–	﹤0.01%	804
2022 Q4	$148K	Buy	14,845 +145	+1%	+$1.55K	﹤0.01%	791
2022 Q3	$155K	Sell	14,700 -221	-1%	-$2.33K	﹤0.01%	753
2022 Q2	$191K	Buy	14,921 +92	+0.6%	+$871	﹤0.01%	734
2022 Q1	$168K	Buy	14,829 +893	+6%	+$11K	﹤0.01%	746
2021 Q4	$216K	Hold	13,936	–	–	﹤0.01%	696
2021 Q3	$246K	Hold	13,936	–	–	﹤0.01%	651
2021 Q2	$354K	Buy	+13,936	New	+$206K	0.01%	550

Other funds holding AVXL

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Brookstone Capital Management's AVXL Position: Q1 2024 in Review

Brookstone Capital Management sold out of Anavex Life Sciences (AVXL) in Q1 2024, closing a stake of 15,185 shares — an estimated $141K sold.

Brookstone Capital Management first reported a position in AVXL in Q2 2021 and held it in 11 quarters. The position peaked at $354K in Q2 2021. 147 funds tracked by Wall St. Rank hold AVXL as of Q1 2024.

Brookstone Capital Management reported no remaining Anavex Life Sciences position as of Q1 2024 after selling out during the quarter.
Brookstone Capital Management sold 15,185 Anavex Life Sciences shares in Q1 2024, an estimated $141K.
Brookstone Capital Management first reported a position in Anavex Life Sciences in Q2 2021 and held it in 11 quarters.
Brookstone Capital Management's Anavex Life Sciences position peaked at $354K in Q2 2021.
147 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2024.

Based on Brookstone Capital Management's 13F filing for Q1 2024, filed 15 Apr 2024.